Nutcracker Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Nutcracker Therapeutics's estimated annual revenue is currently $34.1M per year.
- Nutcracker Therapeutics's estimated revenue per employee is $193,750
- Nutcracker Therapeutics's total funding is $74M.
Employee Data
- Nutcracker Therapeutics has 176 Employees.
- Nutcracker Therapeutics grew their employee count by 3% last year.
Nutcracker Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Co-Founder & CEO | Reveal Email/Phone |
2 | VP and Head Non-Clinical and Clinical Development | Reveal Email/Phone |
3 | Chief Financial Officer | Reveal Email/Phone |
4 | Senior Director Software, Automation, and Anlaytics | Reveal Email/Phone |
5 | Director Facilities, Engineering and EHS | Reveal Email/Phone |
6 | Associate director, supply chain management | Reveal Email/Phone |
7 | NGS Core Facility, Director | Reveal Email/Phone |
8 | Director, IT Operations & Security | Reveal Email/Phone |
9 | Director Information Technology, Program and Project Management | Reveal Email/Phone |
10 | Associate Director, Manufacturing (Plant Head) | Reveal Email/Phone |
Nutcracker Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is Nutcracker Therapeutics?
Nutcracker Therapeutics is an early stage biotech disrupter founded to develop mRNA-based therapeutic drug products which will be manufactured on our novel ACORN (Automation COntroled RNA) microfluidic based manufacturing system. ACORN is a fully automated, software-controlled microfluidics platform. Our advanced technology-driven approach to therapeutics manufacturing addresses significant challenges associated with production and scale-up of therapeutic products. Automation and microfluidics deliver significantly reduced production cycle times, increased process control, efficiency and reproducibility while greatly reducing manual manipulations, risks of contamination and costly facilities. Through the introduction of breakthrough therapeutic micro factories, Nutcracker is poised to deliver on our mission to significantly improve patient's lives.
keywords:N/A
$74M
Total Funding
176
Number of Employees
$34.1M
Revenue (est)
3%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Nutcracker Therapeutics News
Nutcracker Therapeutics' RNA manufacturing platform is at the core of the company's therapeutic effort. It combines RNA biochemistry with...
Nutcracker Therapeutics wants to create mRNA medicines with the push of a button, a tough nut to crack that is now backed by Arch Venture Partners and...
Nutcracker Therapeutics, a biotech developing RNA therapeutics using its proprietary biochip-based manufacturing platform, has raised $167m...
Nutcracker Therapeutics, Inc., an Emeryville, Calif.-based company developing and producing mRNA therapeutics on its proprietary, microfluidic, biochip-based platform, raised $60m in Series B financing. The round was led by Arch Venture Partners with participation from Bluebird Ventures, a firm ...
EMERYVILLE, Calif., Sept. 23, 2020 /PRNewswire/ -- Nutcracker Therapeutics, Inc., a company developing and producing mRNA therapeutics on its proprietary, microfluidic, biochip-based platform, today announced that it has raised $60 million in Series B financing led by ARCH Venture Partners wit ...
Other Companies in Emeryville
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $31.2M | 207 | 4% | $164.5M |
#2 | $41.1M | 212 | 9% | $26.1M |
#3 | $46.5M | 233 | 2% | $396M |
#4 | $64.9M | 236 | 22% | N/A |
#5 | $55M | 238 | 31% | N/A |